Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174590 · ClinicalTrials.gov registry record · Phase 3
Treatment of Major Depressive Disorder With Psychotic Features.
A Phase 3 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00174590 is a Phase 3 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT00174590, a Phase 3 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of risperidone monotherapy in the treatment of psychotic depression. We hypothesize that risperidone is as equally as effective as haloperidol plus sertraline for depression with psychotic features
Interventions
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174590
The ClinicalTrials.gov registry entry for NCT00174590 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risperidone is the first listed.
NCT00174590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174590 about?
NCT00174590 is a clinical study titled "Treatment of Major Depressive Disorder With Psychotic Features.". The purpose of this study is to determine the safety and efficacy of risperidone monotherapy in the treatment of psychotic depression. We hypothesize that risperidone is as equally as effective as haloperidol plus sertraline for depression with psychotic features
What is the current status of trial NCT00174590?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2001-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00174590?
The interventions under investigation include: risperidone (DRUG).
Who is sponsoring clinical trial NCT00174590?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.